Key TakeawaysEli Lilly reported its current treatment for ulcerative colitis, Omvoh, was effective in helping those with Crohn's disease.The Phase 3 trial showed more than half of those taking Omvoh achieved clinical remission in a year.Eli Lilly shares headed toward an all-time closing high on the news. Shares of Eli Lilly (LLY) were on track to close at an all-time high Tuesday as a study showed the pharmaceutical giant’s current drug for ulcerative colitis also was successful in treating Crohn’s disease. ...

Think a friend or colleague should be getting this newsletter? Share this link with them to sign up.Good afternoon! The rivalry between Eli Lilly and Novo Nordisk extends beyond a buzzy class of weight loss and diabetes drugs called GLP-1s. The two drugmakers are also competing to develop once-weekly insulin injections. Those shots could provide a longer-lasting and more convenient option than daily insulin and other common treatments for managing diabetes. Patients with Type 1 diabetes require insulin ever ...

Have Eli Lilly's successes translated into stock performance?Eli Lilly's (NYSE: LLY) broad portfolio of drugs has helped the company's earnings climb over the years -- and in recent times, two products in particular have supercharged growth. The big pharma company sells Mounjaro and Zepbound, both prescribed for weight loss, and demand has been surpassing supply.Pharmaceutical companies are generally viewed as safe investments -- due to people needing their medications no matter what the economy is doing. T ...

Nearly one-half of patients on mirikizumab achieved endoscopic response at 52 weeks; most of these patients were also in clinical remission INDIANAPOLIS, May 21, 2024 /PRNewswire/ -- In Eli Lilly and Company's (NYSE: LLY) pivotal Phase 3 VIVID-1 study, patients with moderately to severely active Crohn's disease, with or without previous biologic failure, achieved statistically significant and clinically meaningful improvements across multiple clinical and endoscopic endpoints at one year with mirikizumab co ...

The three top performing stocks discussed below have appreciated in value by an average of 129.7% in 2024. Such torrid growth logically raises the question of what is possible moving forward. While a conservative investor might suggest that such growth is unsustainable, each of those firms is strongly positioned in the weight-loss pharmaceutical category.Sales of weight loss drugs, led by GLP-1 agonists, are expected to grow at a compound annual rate above 19% between 2023 and 2029. The drugs reduce appetit ...

Eli Lilly’s (LLY) two phase III studies on its once-weekly insulin, efsitora alfa, met their primary endpoint of non-inferior reduction in blood sugar levels compared with daily basal insulins.The patient population in the first phase III study, QWINT-2, comprised type II diabetes (T2D) patients who had never been treated with insulin before (insulin naïve). On the other hand, the phase III QWINT-4 study enrolled adults with T2D who have previously been treated with basal insulin and at least two injections ...

The first-quarter earnings season has come to an end for large drug and biotech companies, with Bayer reporting its results earlier this week. Per the Zacks classification, the pharma/biotech industry comes under the broader Medical sector, which comprises pharma/biotech as well as medical device companies.As of May 15, the Earnings Trends report showed that 87.9% of medical companies beat estimates for earnings and 72.4% beat the same for revenues. While earnings declined 24.3% year over year, revenues ros ...

The future keeps getting brighter for these companies.Drugmakers outside the biosimilar or generic-medicine market must constantly innovate to be successful over long periods. Some are better at it than others.Eli Lilly (LLY 3.19%) and Regeneron Pharmaceuticals (REGN -0.65%) have historically been in the more successful group. That's why they are among the most prominent players in the game.Can Eli Lilly and Regeneron keep this up? Recent developments suggest that the answer is yes. Both companies have anno ...

Efsitora met the primary endpoint in both QWINT-2 and QWINT-4 with once-a-week dosing regimen for people living with type 2 diabetesEfsitora was equally safe and effective among adults naïve to insulin therapy currently using and not using GLP-1 receptor agonistsINDIANAPOLIS, May 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the QWINT-2 and QWINT-4 phase 3 clinical trials evaluating once-weekly insulin efsitora alfa (efsitora) in adults with type 2 ...

Mounjaro manufactured by Eli Lilly and Company packaging is seen in this illustration photo taken in ... [+] a pharmacy in Krakow, Poland on April 9, 2024. (Photo by Jakub Porzycki/NurPhoto via Getty Images)NurPhoto via Getty ImagesEli Lilly (NYSE: LLY) saw its net income decline by $1 billion or 16% y-o-y to $5.2 billion in 2023. This can primarily be attributed to higher acquired in-process research and development expenses (IPR&D). In this note, we discuss Eli Lilly’s margin profile along with its stock ...